SCHEMBL810835

SCHEMBL810835

NC1CCCCC1NS(=O)(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
TP53 P04637 2/20 0.53
SMN1; SMN2 Q16637 3/20 0.48
MAPK1 P28482 2/20 0.48
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
LMNA P02545 4/20 0.45
NFE2L2 Q16236 1/20 0.44
TBXA2R P21731 2/20 0.43
HSP90AA1 P07900 1/20 0.43
KDM4E B2RXH2 2/20 0.42
RECQL P46063 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
MCOLN3 Q8TDD5 1/20 0.42
USP2 O75604 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GAA P10253 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810008 0.84 MAPK1 (0.59) ALDH1A1SMN1; SMN2MAPK1LMNAHSP90AA1
SCHEMBL810572 0.82 ALDH1A1 (0.50) ALDH1A1TP53SMN1; SMN2LMNAHTT
SCHEMBL11759653 0.79 TP53 (0.70) ALDH1A1TP53SMN1; SMN2MAPK1PKM
SCHEMBL810320 0.79 KMT2A (0.52) ALDH1A1SMN1; SMN2LMNANPSR1
SCHEMBL6816353 0.78 ALDH1A1 (0.62) ALDH1A1TP53SMN1; SMN2LMNAKDM4E
SCHEMBL810319 0.78 ALDH1A1 (0.62) ALDH1A1TP53SMN1; SMN2LMNAKDM4E
SCHEMBL5430216 0.78 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2MAPK1LMNAKDM4E
SCHEMBL987578 0.78 ALDH1A1 (0.62) ALDH1A1TP53SMN1; SMN2LMNAKDM4E
SCHEMBL28380213 0.78 RECQL (0.50) ALDH1A1SMN1; SMN2MAPK1LMNAKDM4E
SCHEMBL28393319 0.78 RECQL (0.50) ALDH1A1SMN1; SMN2MAPK1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2399895-B1 Process for producing optically active aliphatic fluoroalcohol KANTO KAGAKU (JP) 2018-08-08 EP disclosed
US-8558033-B2 Process for producing optically active aliphatic fluoroalcohol KANTO KAGAKU KABUSHIKI KAISHA (JP) 2013-10-15 US disclosed
US-20110319671-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE ALIPHATIC FLUOROALCOHOL KANTO KAGAKU KABUSHIKI KAISHA (JP) 2011-12-29 US disclosed
EP-2399895-A2 Process for producing optically active aliphatic fluoroalcohol Kanto Kagaku Kabushiki Kaisha (JP) 2011-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319671-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE ALIPHATIC FLUOROALCOHOL ADH1A, ADH1C, ADH5 ALDH1A1 5/4885TP53 4512/4885SMN1; SMN2 4275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.